Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Josep M. Llovet, Gar-Yang Chau et al.|The Lancet Oncology|2015Cited by 1.1k
STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)Jordi Bruix, Josep M. Llovet, Tadatoshi Takayama et al.|Journal of Clinical Oncology|2014Cited by 60